Santhera Pharmaceuticals has announced the appointment of Orlando Oliveira as its new Chief Executive Officer, effective July 15, 2026, succeeding Dario Eklund, who has led the company through a transformative phase over the past six and a half years. Oliveira brings over 25 years of extensive experience in the biopharma sector, with a strong background in specialty pharmaceuticals, oncology, and rare diseases, positioning him to guide Santhera’s growth trajectory as it capitalizes on its recent advancements.

Under Eklund’s leadership, Santhera transitioned into a focused commercial-stage entity centered on AGAMREE® (vamorolone), a novel treatment for Duchenne muscular dystrophy (DMD). Eklund successfully navigated the company through significant challenges, culminating in the product’s approvals in the U.S., Europe, and the UK, with launches planned for 2024. His tenure also saw the strengthening of Santhera’s financial and operational foundations, as well as the establishment of strategic partnerships that broadened the company’s global footprint.

The transition in leadership signals a pivotal moment for Santhera, as Oliveira’s extensive commercial experience will be crucial in scaling the company’s operations and advancing its therapeutic pipeline. This leadership change reinforces the importance of strategic renewal in biopharma, particularly as Santhera aims to leverage AGAMREE’s market potential while addressing unmet medical needs in rare diseases. The incoming CEO’s focus on building high-performing organizations and executing strategic initiatives is likely to accelerate Santhera’s growth and enhance its competitive position in the biotech landscape.

Source: globenewswire.com